Play all audios:
ABSTRACT The nonmedical use of synthetic cathinones is increasing on a global scale. 4-Methyl-_N_-methylcathinone (mephedrone) is a popular synthetic cathinone that is now illegal in the
United States and other countries. Since the legislative ban on mephedrone, a number of ‘second-generation’ analogs have appeared in the street drug marketplace, including
4-methyl-_N-_ethylcathinone (4-MEC) and 4′-methyl-_α_-pyrrolidinopropiophenone (4-MePPP). Here we characterized the interactions of 4-MEC and 4-MePPP with transporters for 5-HT (SERT) and
dopamine (DAT) using molecular, cellular, and whole-animal methods. _In vitro_ transporter assays revealed that 4-MEC displays unusual ‘hybrid’ activity as a SERT substrate (ie, 5-HT
releaser) and DAT blocker, whereas 4-MePPP is a blocker at both transporters but more potent at DAT. _In vivo_ microdialysis experiments in rat brain demonstrated that 4-MEC (1–3 mg/kg,
i.v.) produced large increases in extracellular 5-HT, small increases in dopamine, and minimal motor stimulation. In contrast, 4-MePPP (1–3 mg/kg, i.v.) produced selective increases in
dopamine and robust motor stimulation. Consistent with its activity as a SERT substrate, 4-MEC evoked inward current in SERT-expressing _Xenopus_ oocytes, whereas 4-MePPP was inactive in
this regard. To examine drug–transporter interactions at the molecular level, we modeled the fit of 4-MEC and 4-MePPP into the binding pockets for DAT and SERT. Subtle distinctions in
ligand–transporter binding were found that account for the differential effects of 4-MEC and 4-MePPP at SERT. Collectively, our results provide key information about the pharmacology of
newly emerging mephedrone analogs, and give clues to structural requirements that govern drug selectivity at DAT _vs_ SERT. SIMILAR CONTENT BEING VIEWED BY OTHERS
(2-AMINOPROPYL)BENZO[Β]THIOPHENES (APBTS) ARE NOVEL MONOAMINE TRANSPORTER LIGANDS THAT LACK STIMULANT EFFECTS BUT DISPLAY PSYCHEDELIC-LIKE ACTIVITY IN MICE Article 08 November 2021 STRUCTURE
OF THE HUMAN DOPAMINE TRANSPORTER AND MECHANISMS OF INHIBITION Article Open access 07 August 2024 ETHANOL INHIBITS DOPAMINE UPTAKE VIA ORGANIC CATION TRANSPORTER 3: IMPLICATIONS FOR ETHANOL
AND COCAINE CO-ABUSE Article Open access 13 June 2023 INTRODUCTION In recent years, there has been an alarming increase in the nonmedical use of synthetic psychoactive compounds described
as ‘designer drugs’ or ‘legal highs’ (Rosenbaum et al, 2012). These substances are synthesized by rogue chemists who hijack the medical and patent literature to identify structures that
target specific neuronal receptors or transporters known to mediate psychoactive effects (Lewin et al, 2014). Synthetic cathinones are designer drugs given innocuous names like ‘bath salts’,
‘plant food’, or ‘research chemicals’ as a ploy to skirt the regulations governing the sale of psychoactive substances (Baumann et al, 2013a; De Felice et al, 2014).
4-Methyl-_N_-methylcathinone (mephedrone) and 3,4-methylenedioxypyrovalerone (MDPV) are examples of synthetic cathinones that produce stimulant-like subjective effects at low doses, but
dangerous side effects after high doses or chronic use (Dargan et al, 2011; Spiller et al, 2011). Adverse consequences include hypertension, tachycardia, anxiety, hallucinations, psychosis,
and even death. Because of public health risks, legislative authorities have banned mephedrone, MDPV, and certain other synthetic cathinones in the United States (Drug Enforcement
Administration (DEA), Department of Justice, 2013), and similar legislation has been enacted in European countries. In response to legislative bans, enterprising chemists have synthesized a
number of ‘second-generation’ replacement analogs as a means to evade regulatory control, and this trend is expected to continue (Leffler et al, 2014; Marinetti and Antonides, 2013). Like
other stimulant drugs, synthetic cathinones exert their pharmacological effects by disrupting the function of solute carrier SLC6 transporter proteins (ie, monoamine transporters) expressed
on nerve cells in the brain and periphery (Baumann et al, 2013a; Hadlock et al, 2011; Lopez-Arnau et al, 2012). Monoamine transporters normally mediate the sodium-dependent reuptake of
monoamine neurotransmitters, and there are specific transporter proteins for norepinephrine (NET), dopamine (DAT), and 5-HT (SERT) (Kristensen et al, 2011). Drugs that interact with
transporters can be categorized as either amphetamine-like substrates or cocaine-like blockers (Rothman and Baumann, 2003; Sitte and Freissmuth, 2010). Both types of drugs increase
extracellular concentrations of monoamines in nervous tissue, but substrates induce transporter-mediated sodium currents (ie, depolarization) and evoke transmitter efflux (ie, release),
whereas blockers do not. Importantly, determining the precise molecular mechanism of action for transporter drugs is critical to predict their putative toxic potential (Baumann et al, 2014;
Steinkellner et al, 2011). Previous studies have shown that mephedrone targets monoamine transporters as a nonselective substrate, thereby evoking the release of norepinephrine, dopamine,
and 5-HT (Baumann et al, 2012; Cameron et al, 2013; Eshleman et al, 2013; Simmler et al, 2013). In contrast, MDPV is a potent blocker at NET and DAT with little influence on SERT. Systemic
administration of mephedrone or MDPV to rats increases extracellular concentrations of dopamine in mesolimbic reward pathways, indicating the potential for addiction (Baumann et al, 2012,
2013b; Kehr et al, 2011; Wright et al, 2012). Accordingly, both drugs are readily self-administered and facilitate intracranial self-stimulation in rat models (Aarde et al, 2013a; Bonano et
al, 2014; Hadlock et al, 2011; Watterson et al, 2014). As noted above, a number of second-generation analogs of mephedrone and MDPV have recently appeared in the recreational drug
marketplace (Leffler et al, 2014; Marinetti and Antonides, 2013). We and others have shown that newly emerging analogs of MDPV, like _α_-pyrrolidinovalerophenone (_α_-PVP), are potent
blockers at DAT and NET (Kolanos et al, 2013; Marusich et al, 2014). However, little information is available regarding the molecular mechanisms and pharmacological effects of mephedrone
analogs (ie, 4-methyl ring-substituted compounds) such as 4-methyl-_N_-ethylcathinone (4-MEC) and 4′-methyl-_α_-pyrrolidinopropiophenone (4-MePPP). Figure 1 shows the chemical structures of
4-MEC and 4-MePPP as compared with mephedrone; both drugs maintain the 4-methyl ring-substitution of mephedrone, but 4-MEC has an _N-_ethyl group whereas 4-MePPP has an _N_-butyl group that
is cyclized to form a pyrrolidine ring. 4-MEC has been identified in products purchased from internet vendors (eg, NRG-2) (Ayres and Bond, 2012), and the drug is associated with adverse
medical consequences (Gil et al, 2013; Rojek et al, 2014). 4-MePPP was available as a recreational stimulant in the late 1990s and was scheduled by the German Controlled Substance Act that
prohibited its sale and use. Initial studies with 4-MePPP involved the characterization of its metabolism and development of forensic assays to detect the drug in biological matrices
(Springer et al, 2003; Springer et al, 2002). 4-MePPP has reappeared recently in products containing mixtures of cathinone-related compounds (eg, NRG-3) (Brandt et al, 2011). In the present
study, we employed molecular, cellular, and whole-animal methods to examine the interactions of 4-MEC and 4-MePPP with monoamine transporters. _In vitro_ transporter assays were carried out
in rat brain synaptosomes and in cells expressing human transporters. Effects of drugs on _in vivo_ neurochemistry were monitored using microdialysis in rat nucleus accumbens. Finally, we
analyzed transporter-mediated currents evoked by these drugs in _Xenopus_ oocytes expressing SERT. Our results reveal diverse profiles of transporter activity for 4-MEC and 4-MePPP when
compared with mephedrone. MATERIALS AND METHODS DRUGS AND REAGENTS For uptake and release assays in synaptosomes, [3H]dopamine, [3H]5-HT, and [3H]1-methyl-4-phenylpyridinium ([3H]MPP+) were
purchased from Dupont New England Nuclear (Boston, MA). All reagents, buffer salts, and chemicals were obtained from Sigma Chemical (St Louis, MO) unless otherwise noted. Reagents used in
the experiments for uptake and efflux assays in cells were purchased and used according to previous work (Hofmaier et al, 2014). Plasmids encoding human SERT were a generous gift of Dr Randy
D Blakely. ANIMALS AND HOUSING Male Sprague-Dawley rats (Charles River, Wilmington, MA) weighing 250–350 g were housed in standard conditions (lights on 0700–1900 h) with food and water
freely available. Rats were maintained in facilities fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and experiments were performed in
accordance with the Institutional Care and Use Committee of the NIDA IRP. _Xenopus laevis_ frogs (Nasco, Fort Atkinson, WI) were kept in aquaria on a strict 12 h light/dark schedule with
food available once weekly. UPTAKE AND RELEASE ASSAY IN RAT BRAIN SYNAPTOSOMES Uptake and release assays were carried out in rat brain synaptosomes as previously described (Baumann et al,
2013b). Synaptosomes were prepared from rat striatum for DAT assays, whereas synaptosomes were prepared from whole brain minus striatum and cerebellum for SERT assays. For uptake inhibition
assays, 5 nM [3H]dopamine and [3H]5-HT were used to assess transport activity at DAT and SERT, respectively. The selectivity of uptake assays was optimized for a single transporter by
including unlabeled blockers to prevent uptake of [3H]transmitter by competing transporters. Uptake inhibition assays were initiated by adding 100 μl of tissue suspension to 900 μl
Krebs-phosphate buffer containing test drug and [3H]transmitter. Uptake inhibition assays were terminated by rapid vacuum filtration through Whatman GF/B filters, and retained radioactivity
was quantified by liquid scintillation counting. For release assays, 9 nM [3H]MPP+ was used as the radiolabeled substrate for DAT, whereas 5 nM [3H]5-HT was used as the radiolabeled
substrate for SERT. All buffers used in the release assays contained 1 μM reserpine to block vesicular uptake of substrates. The selectivity of release assays was optimized for a single
transporter by including unlabeled blockers to prevent the uptake of [3H]MPP+ or [3H]5-HT by competing transporters. Synaptosomes were preloaded with radiolabeled substrate in
Krebs-phosphate buffer for 1 h (steady state). Release assays were initiated by adding 850 μl of preloaded synaptosomes to 150 μl of test drug. Release was terminated by vacuum filtration
and retained radioactivity was quantified as described for uptake inhibition. _IN VIVO_ MICRODIALYSIS IN RAT NUCLEUS ACCUMBENS Microdialysis procedures were carried out as previously
described (Baumann et al, 2012). Male rats were surgically prepared with jugular catheters and intracerebral guide cannulae aimed at the nucleus accumbens (AP +1.6 mm, ML −1.7 mm relative to
bregma; −6.2 mm relative to dura). After a 7–10-day recovery period, catheters were attached to extension tubes and 0.5 × 2 mm microdialysis probes (CMA/12, Harvard Apparatus, Holliston,
MA) were inserted into guide cannulae. Ringer’s solution was perfused through the probe at 0.5 μl/min and dialysate samples were collected at 20 min intervals. Drug treatments were given
after three stable baseline samples were obtained. Rats received two i.v. drug injections, 1 mg/kg at time 0 followed by 3 mg/kg 60 min later. Control rats received two i.v. saline
injections on the same schedule. Concentrations of 5-HT and dopamine were quantified using high-pressure liquid chromatography coupled to electrochemical detection (HPLC-ECD). Dialysate
samples were injected onto a microbore HPLC column coupled to an EC detector with a glassy carbon electrode set at +650 mV relative to Ag/AgCl reference. Mobile phase was pumped at 60
μl/min. Chromatographic data were exported to an Empower software system (Waters, Milford, MA) for peak identification, integration, and analysis. UPTAKE AND RELEASE ASSAY IN HEK293 CELLS
The uptake and release assays in HEK293 cells were carried out as previously described (Hofmaier et al, 2014). For uptake assays, cells were washed twice with Krebs HEPES buffer. Test drugs
were added to cells for 5 min allowing equilibration with transporters. Subsequently, [3H]5-HT and [3H]dopamine were added, and the reaction was stopped after allowing uptake for 1 min. The
uptake was terminated by washing with 500 μl of ice-cold Krebs HEPES buffer, cells were lysed with 500 μl of 1% sodium dodecyl sulfate, and tritium was counted on a Packard 2300 TR TriCarb
Liquid Scintillation Analyzer. For release studies, HEK293 cells expressing hSERT or hDAT were grown overnight on round glass coverslips (5-mm diameter, 40 000 cells per coverslip) placed in
a 96-well plate and preloaded with 0.4 μM [3H]5HT or 0.03 μM [3H]MPP+ for 20 min at 37 °C in a final volume of 0.1 ml/well. Coverslips were transferred to small chambers (0.2 ml) and
superfused with Krebs HEPES buffer (25 °C, 0.7 ml/min). The 40 min baseline for efflux of radioactivity was followed by addition of test drugs and collection of fractions every 2 min. The
experiment was terminated by lysis of the cells with 1% sodium dodecyl sulfate and counted. ELECTROPHYSIOLOGICAL RECORDINGS IN _X. LAEVIS_ OOCYTES Electrophysiology recordings were performed
as recently described (Baumann et al, 2014). Briefly, the plasmid containing hSERT was linearized and _in vitro_ transcription was carried out using a T7 RNA polymerase Kit mMessage
mMachine (Ambion, Life Technologies, Grand Island, NY). Stage V–VI oocytes were obtained from _X. laevis_ and transferred to calcium-free Ringer’s solution. The oocytes were separated into
smaller lobes containing 3 to 5 oocytes and defolliculated by enzymatic digestion with collagenase from _Clostridium histolyticum_ (1 mg/ml) for 60 min. Oocytes were selected and transferred
to Ringer’s solution. Oocytes were kept at 18 °C in Ringer’s solution containing 2.5 mM sodium pyruvate, 100 μg/ml penicillin, and 100 μg/ml streptomycin. In each oocyte, 10 ng of the
prepared hSERT RNA was microinjected. The oocytes were maintained for 7–10 days for functional studies, and solution was changed twice daily. A CA-1B high-performance oocyte clamp was
employed for the measurements. The recorded signal was digitized with Digidata 13222A (Axon Instruments, Molecular Devices, Sunnyvale, CA). An Intel PC running pCLAMP 9.2 (Axon Instruments)
was used for acquisition. Borosilicate glass capillaries were pulled to a final resistance of 0.4–1.2 MΩ and filled with 3 M KCl. Oocytes were impaled and the membrane potential was clamped
to a holding potential of −60 mV. For continuous superfusion with ND100 solution (100 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH adjusted to 7.4 with NaOH), a gravity-driven
superfusion system was used. Recordings were started after a stable current baseline was established. The current was sampled with 100 Hz and low pass filtered with 20 Hz. LIGAND AND PROTEIN
MODEL PREPARATION The ligand structures were built as (_S_)-enantiomers in protonated form using the software MOE (Molecular Operating Environment (MOE), Montreal, QC, Canada). The recently
crystallized _Drosophila_ DAT, in the outward facing conformation in complex with nortriptyline (dDATcryst), was used as a template for transporter modeling (Penmatsa et al, 2013). dDAT
displays close to 70% sequence homology with hSERT, hDAT, and hNET in the substrate-binding pocket. Sequence alignment was performed using ClustalX (Thompson et al, 2002). Nonstructural
waters were removed from the dDATcryst structure and 250 homology models of each of the human transporters in complex with nortriptyline were created using Modeller 9.11 (Sali et al, 1995).
Nortriptyline has dissociation constants (_K_D) of 18 nM at hSERT, 1140 nM at hDAT, and 4.4 nM at hNET (Tatsumi et al, 1997). The models with the highest ‘Discrete Optimization of Protein
Energy’ (DOPE) score showed no disallowed dihedrals near the central binding site and were protonated at pH 7 using the Protonate3D tool in MOE. Nortriptyline and residues within a radius of
5 Å were energy minimized using a distance-dependent dielectric constant of 2 (Hou et al, 2011) to 80 in the OPLS-AA force field (Jorgensen et al, 1996). DOCKING OF 4-MEC AND 4-MEPPP In
order to determine the influence of the SERT Thr439 conformation on ligand placement, the side chain was rotated by 180° along its C_α_–C_β_ bond. The binding site topology was optimized by
energy minimization of nortriptyline (or Thr439 in SERT) as noted above for dDAT (Hou et al, 2011; Jorgensen et al, 1996). The transporter–ligand complexes were loaded into the docking
software GOLD 5.2 (Jones et al, 1997) that uses a genetic algorithm to obtain poses nondeterministically. Waters were removed and the binding site was defined as the center of mass of the
inhibitor. The cathinone substructure was used for setting restraints, whereby the cationic nitrogen was forced to be within 2–4 Å to the Tyr95/Phe76 (SERT/DAT) backbone carbonyl oxygen.
This is in analogy to the positive partial charge density of antidepressant ligands in dDATcryst and in the humanized leucine transporter structures (Wang et al, 2013). Binding modes were
generated 50 times per ligand using GoldScore with maximum search efficiency, and the poses retrieved were clustered based on their placement into specific subpockets. DATA ANALYSIS AND
STATISTICS For uptake and release assays, the data from three experiments were fit to a dose–response curve equation, and IC50 or EC50 values were calculated using GraphPad Prism. For
microdialysis experiments, the first three samples collected were considered baseline samples and all subsequent monoamine measures were expressed as a percentage of the mean of this
baseline. Effects of drugs on dialysate 5-HT and dopamine were evaluated using two-way ANOVA (treatment × time) followed by Bonferroni _post hoc_ tests at specific time points after drug
injection. For transporter-mediated currents, the comparison of the maximum currents across drugs was analyzed by one-way ANOVA with Tukey’s _post hoc_ test. _P_<0.05 was chosen as the
minimum criterion for statistical significance. RESULTS EFFECTS OF 4-MEC AND 4-MEPPP ON DAT AND SERT IN SYNAPTOSOMES Figure 2 depicts the effects of mephedrone, 4-MEC, and 4-MePPP in
transporter assays carried out in rat brain synaptosomes. The ability of test drugs to inhibit uptake of [3H]5-HT and [3H]dopamine is shown in Figure 2a and b, respectively. Mephedrone and
4-MEC displayed nearly equal potency at inhibiting uptake at SERT (IC50=∼500 nM) and at DAT (IC50=∼800 nM). In contrast, 4-MePPP was much more potent as an inhibitor at DAT when compared
with SERT, with an IC50=215±13 nM at DAT _vs_ IC50=>10 000 nM at SERT. Thus, mephedrone and 4-MEC are nonselective uptake blockers, whereas 4-MePPP is 40-fold selective for DAT over SERT.
As discussed in previous publications (Baumann et al, 2012, 2013a), the effects of drugs in uptake inhibition assays cannot reveal whether drugs are acting as transporter blockers or
substrates, and hence we next tested the effects of drugs in the synaptosome release assay. The ability of test drugs to evoke release of preloaded [3H]5-HT and [3H]MPP+ is shown in Figure
2c and d, respectively. Mephedrone and 4-MEC displayed similar potency in their ability to evoke [3H]5-HT release from SERT (EC50=∼100 nM), whereas 4-MePPP was inactive as a releaser at
SERT. Interestingly, mephedrone was a fully efficacious releaser of [3H]MPP+ at DAT (EC50=39±3 nM), but 4-MEC and 4-MePPP were both inactive in this regard. EFFECTS OF 4-MEC AND 4-MEPPP ON
NEUROCHEMISTRY AND BEHAVIOR _IN VIVO_ Figure 3 depicts the effects of i.v. administration of 4-MEC and 4-MePPP on neurochemistry and locomotor activity in rats undergoing microdialysis in
the nucleus accumbens. Figure 3a demonstrates a main effect of drug treatment on extracellular 5-HT (F2, 16=34.38, _p_<0.0001). 4-MEC produced significant dose-related increases in
extracellular 5-HT, with 1 mg/kg producing a 3.2-fold elevation above baseline, and 3 mg/kg producing a 6.9-fold elevation. In marked contrast, 4-MePPP had no significant effect on
extracellular 5-HT at either dose tested. Figure 3b shows a main effect of drug treatment on extracellular dopamine (F2, 16=27.26, _p_<0.0001), and the effects of 4-MEC and 4-MePPP on
dopamine were opposite to the changes in 5-HT. More specifically, 4-MePPP produced dose-related increases in extracellular dopamine, with 1 mg/kg producing a 1.8-fold elevation above
baseline and 3 mg/kg producing a 3.3-fold elevation. 4-MEC, on the other hand, produced no effect on dopamine at 1 mg/kg, but a 1.9-fold increase after the 3 mg/kg dose. Figure 3c and d
demonstrate that drug treatment had main effects on forward locomotion (F2, 16=40.66, _p_<0.0001) and stereotypy (F2, 16=20.98, _p_<0.0001). 4-MEC produced small increases in both
parameters, but only after the high dose; 4-MePPP produced striking dose-related effects that were much greater than the effects of 4-MEC. Importantly, the motor effects of both drugs were
short-lived and quickly returned to baseline values by 60 min after injection. EFFECTS OF 4-MEC AND 4-MEPPP ON HUMAN TRANSPORTERS EXPRESSED IN CELLS Based on the results from rat
experiments, we wished to explore the molecular mechanism of action for 4-MEC and 4-MePPP in greater detail, and hence the effects of these drugs were examined in HEK293 cells stably
expressing human transporters. Figure 4a and b show the effects of test drugs on uptake inhibition in cells expressing human SERT (hSERT) or human DAT (hDAT), respectively. In agreement with
findings from synaptosomes, 4-MEC showed nonselective inhibition of uptake, with IC50 values of 10.9±2.2 μM at hSERT and 3.9±0.4 μM at hDAT. In contrast, 4-MePPP displayed much higher
potency at inhibiting uptake at hDAT (IC50=1.08±0.1 μM) when compared with hSERT (IC50=126±36 μM). Next, we compared the effects of 4-MEC and 4-MePPP on transporter-mediated efflux using
superfusion methods. In these experiments, the time-dependent efflux of [3H]5-HT through hSERT and [3H]MPP+ through hDAT was assessed in the presence or absence of monensin (10 μM), an
ionophore that dissipates the normal Na+ gradient across cell membranes and selectively enhances the efflux caused by transporter substrates (Baumann et al, 2013b; Scholze et al, 2000).
Thus, monensin can be used to discriminate the effects of transporter substrates _vs_ blockers. Figure 4c shows that 4-MEC (10 μM) induced efflux of [3H]5-HT but 4-MePPP did not.
Importantly, the efflux of [3H]5-HT produced by 4-MEC was dramatically enhanced in the presence of monensin, confirming that 4-MEC is a substrate at hSERT. Figure 4d demonstrates that 4-MEC
and 4-MePPP both induced modest efflux of [3H]MPP+ at hDAT, but in neither case was this response altered by monensin. EFFECTS OF 4-MEC AND 4-MEPPP ON SERT-MEDIATED CURRENTS As a final test
to confirm that 4-MEC and 4-MePPP display differential effects at SERT, we examined transporter-mediated currents in oocytes expressing hSERT (Baumann et al, 2014). For these experiments,
the effects of drugs were only evaluated in SERT-expressing cells as neither drug elicited substrate activity at DAT. Figure 5a and b depict the effects of 4-MEC and 4-MePPP on SERT-mediated
currents, respectively. 4-MEC evoked robust dose-related inward currents that followed a bell-shaped dose response. The greatest magnitude of current produced by 4-MEC (30 μM) was nearly
equivalent to that produced by 10 μM 5-HT. Consistent with the profile of a transporter blocker, 4-MePPP did not elicit any transporter mediated-current at doses up to 100 μM. Figure 5c
shows the current-inducing effects of 4-MEC and 4-MePPP when normalized to the effects of 10 μM 5-HT. This figure highlights the bell-shaped dose response for 4-MEC and the lack of effect
for 4-MePPP. COMPUTATIONAL DOCKING WITH 4-MEC AND 4-MEPPP The differential effects of 4-MEC and 4-MePPP at SERT prompted us to employ a molecular docking approach to explore the structural
peculiarities between SERT and DAT, and possible differences in the binding modes of the two compounds. The binding modes of the two cathinones in the hSERT and hDAT homology models were
analogous to the LeuBAT inhibitor binding mode (Wang et al, 2013), whereby the aromatic rings are placed in the previously reported subpocket B (Andersen et al, 2010; Seddik et al, 2013).
4-MEC and 4-MePPP only differ in their _N_-substitution, with 4-MePPP having a sterically more demanding substituent (pyrrolidine ring _vs_ ethyl chain). Remarkably, this difference causes a
>100-fold decrease in the affinity of 4-MePPP for SERT _vs_ DAT. It seems unlikely that this is solely due to differences in the interaction of the cathinone nitrogen with distinct amino
acids, as the only difference in the binding site is F76/Y95 (Table 1). Figure 6 depicts docking poses of 4-MEC and 4-MePPP in hDAT (Figure 6a) and hSERT (Figure 6b and c). Although both
compounds show analogous poses in hDAT, which is supported by their similar effects at inhibiting [3H]dopamine uptake, the placement in hSERT is less consistent. Importantly, this
inconsistency only affects 4-MePPP, which shows two clusters, with the aromatic moiety being placed either deeper in subpocket B or in subpocket C. The latter configuration seems unlikely,
as no transporter inhibitor was found to occupy this site in LeuBATs. Thus, the ambiguous positioning of 4-MePPP in hSERT might be because of its larger _N_-pyrrolidino substituent that
forces a slight shift deeper into subpocket B when compared with the case for 4-MEC. In the case of subpocket B of hDAT, there is sufficient space to accommodate 4-MePPP because of the
smaller side chains present (ie, Ala423, Val152, and Gly153); subpocket B in hSERT is formed by bulkier amino-acid side chains (Thr439, Ile172, and Ala173). In particular, Thr439 might be
responsible for steric repulsion of 4-MePPP in hSERT, rendering the complex less stable. Thus, two different side chain conformations of Thr439 were probed and similar docking patterns were
found (Figure 6b and c), whereby either the polar hydroxyl group or a proximal methyl group repels the positioning of 4-MePPP. In addition, reducing the flexibility of Thr439 upon binding of
4-MePPP also leads to an entropically unfavorable contribution to the binding free energy. DISCUSSION A major goal of our study was to determine the mechanism of action and pharmacological
effects of the mephedrone analogs, 4-MEC and 4-MePPP. In previous publications, we and others have shown that mephedrone is a nonselective substrate for monoamine transporters, thereby
causing the release of 5-HT, dopamine, and norepinephrine (Baumann et al, 2012; Eshleman et al, 2013; Simmler et al, 2013). Once legislation was enacted to render mephedrone illegal, 4-MEC
and 4-MePPP began appearing in the recreational drug marketplace (Ayres and Bond, 2012; Brandt et al, 2011; Leffler et al, 2014), and 4-MEC has been associated with adverse medical
consequences leading to death (Gil et al, 2013; Rojek et al, 2014). The present _in vitro_ findings from rat brain synaptosomes show that 4-MEC displays unique activity as a SERT
substrate/DAT blocker, whereas 4-MePPP is a DAT blocker with little activity at SERT. Consistent with synaptosome data, i.v. administration of 4-MEC induces predominant elevations in brain
extracellular 5-HT, whereas 4-MePPP induces selective elevations in dopamine. Importantly, the effects of 4-MEC and 4-MePPP in cells expressing human transporters agree with the findings in
rat brain synaptosomes. Using molecular modeling techniques, we provide evidence that differences in amino-acid composition of the ligand-binding pockets of hDAT and hSERT can explain the
ability of 4-MePPP to selectively interact with hDAT. Overall, our findings reinforce the concept that subtle changes in cathinone structure can dramatically alter drug pharmacology. One of
the most interesting findings from our experiments in synaptosomes is the unusual transporter activity of 4-MEC as compared with mephedrone. 4-MEC represents a rare example of a compound
that exhibits substrate activity at SERT and blocker activity at DAT, a profile that we call ‘hybrid’ transporter activity. Simmler et al (2014) reported data consistent with our findings,
showing 4-MEC is a 5-HT releaser but a blocker at hDAT and hNET. Although this profile is unusual, it has been reported previously (Blough et al, 2014; Simmler et al, 2014; Yu et al, 2000).
Yu et al (2000) described SERT substrate/DAT blocker activity for _N-_ethylaminopropiophenone (ie, _N-_ethylcathinone), a bioactive metabolite of the clinically available appetite
suppressant diethylpropion. 4-MEC and _N-_ethylcathinone display similar chemical structures, and hence it appears that extension of the _N-_alkyl chain of cathinone compounds, from
_N-_methyl to _N-_ethyl, is sufficient to convert activity at DAT from a substrate (eg, mephedrone) to a blocker (eg, 4-MEC). In contrast, mephedrone and 4-MEC display nearly equivalent
effects as 5-HT releasers, suggesting that minor changes in _N-_alkyl chain length do not alter substrate activity at SERT. The data with 4-MEC and _N-_ethylcathinone illustrate the close
structural resemblance among synthetic cathinones in the ‘street drug’ marketplace and those being prescribed clinically, such as diethylpropion and bupropion (Carroll et al, 2014; Cercato
et al, 2009). Indeed, Blough et al (2014) have proposed that hybrid transporter compounds based on the _N-_cyclopropylcathinone structure could have value in the treatment of substance use
disorders. Future studies should be carried out to examine the possible therapeutic potential of hybrid transporter ligands. Extending the _N-_alkyl chain of 4-MEC to form the pyrrolidine
ring structure of 4-MePPP has marked effects on pharmacology, converting the compound to a DAT-selective transporter blocker. In fact, the _in vitro_ pharmacology of 4-MePPP resembles that
of pyrrolidinophenone compounds like pyrovalerone and MDPV rather than mephedrone (Baumann et al, 2013b; Cameron et al, 2013; Kolanos et al, 2013; Marusich et al, 2014). Meltzer et al (2006)
reported that pyrovalerone analogs are potent blockers at DAT and NET with little influence on SERT. More recently, we demonstrated that MDPV, _α_-PVP, and related pyrrolidinophenones are
potent and selective blockers at DAT and NET in rat brain synaptosomes (Baumann et al, 2013b; Marusich et al, 2014). Kolanos et al (2013) examined the effects of MDPV and _α_-PVP in
_Xenopus_ oocytes expressing hDAT and found that these compounds do not induce inward DAT-mediated currents, consistent with the present results showing that 4-MePPP does not display DAT
substrate activity. Collectively, the _in vitro_ data indicate that cathinone analogs that possess a pyrrolidine ring structure, or perhaps other bulky _N-_alkyl substituents, will function
as selective uptake blockers at DAT and NET. The present microdialysis results show that transporter activity of 4-MEC and 4-MePPP strongly influences the _in vivo_ neurochemical and
behavioral effects of the drugs. Administration of 4-MEC to rats produces predominant increases in extracellular 5-HT with small increases in extracellular dopamine, consistent with its
hybrid transporter actions. The _in vivo_ neurochemical profile of 4-MEC mimics the effects of mephedrone and methylone (Baumann et al, 2012; Kehr et al, 2011; Wright et al, 2012), but 4-MEC
is less potent and has weaker effects on dopamine when compared with other ring-substituted cathinones. Previous studies have shown that 5-HT-releasing actions of amphetamines and
cathinones can dampen dopamine-mediated locomotor and reinforcing effects in rats (Baumann et al, 2011; Bonano et al, 2014), and hence it might be predicted that 4-MEC has weak stimulant
properties. In contrast, 4-MePPP produces selective increases in extracellular dopamine and robust locomotor activation. The _in vivo_ neurochemical profile of 4-MePPP mimics the effects of
MDPV (Baumann et al, 2013b), but 4-MePPP is 10-fold less potent and its effects are short-lived. It is well established that elevations in extracellular dopamine in the nucleus accumbens are
correlated with the magnitude of locomotor activation produced by stimulant drugs (Baumann et al, 2011; Zolkowska et al, 2009), and the hyperactivity produced by 4-MePPP agrees with the
reported locomotor effects of MDPV and related pyrrolidinophenones (Aarde et al, 2013b; Fantegrossi et al, 2013; Gatch et al, 2013; Marusich et al, 2014; Marusich et al, 2012). The selective
increase in extracellular dopamine produced by 4-MePPP suggests that this drug will be readily self-administered (Aarde et al, 2013b; Watterson et al, 2014). Our experiments in synaptosomes
provide the advantage of rapid drug screening in native tissue, whereas experiments in cells allow a more detailed assessment of drug–transporter interactions. Here we examined the effects
of 4-MEC and 4-MePPP in cells expressing hDAT and hSERT. In uptake inhibition assays, 4-MEC acts as a nonselective transporter blocker whereas 4-MePPP is selective for hDAT, in agreement
with the findings in synaptosomes. It is noteworthy that IC50 values for 4-MEC and 4-MePPP in transporter-expressing cells are somewhat higher (ie, apparent lower potency) than those
determined in synaptosomes. Differences in assay procedures used for synaptosomes _vs_ cells could explain these differences. In addition, the complement of accessory membrane proteins
present in synaptosomes may not be present in nonneuronal cell systems (Wilhelm et al, 2014), and this could influence absolute potency values. In the superfusion assays, 4-MEC evokes 5-HT
efflux whereas 4-MePPP does not. The 5-HT efflux produced by 4-MEC is markedly potentiated by monensin, an ionophore that dissipates Na+ gradients across cell membranes enhancing
intracellular Na+ (Hofmaier et al, 2014). We have shown previously that monensin augments transporter-mediated efflux caused by substrates but not blockers (Baumann et al, 2013b; Hofmaier et
al, 2014; Scholze et al, 2000), and hence the findings with monensin reported here provide decisive evidence that 4-MEC is a SERT substrate. 4-MEC and 4-MePPP also evoke modest efflux from
hDAT, but these effects are not altered by monensin, confirming that neither drug is a DAT substrate. Our data from cells expressing human transporters reinforce the findings from rat brain
tissue, and serve to validate the translational value of studying cathinone-type drugs in rodent models. Perhaps the most sophisticated method for examining the interactions of drugs with
monoamine transporters involves the measurement of transporter-mediated ionic currents (Sitte et al, 1998; Sonders et al, 1997). Because the SLC6 transporters co-transport Na+ ions along
with substrate, inward depolarizing current is generated during translocation of substrate from the outside of the cell to the inside (Kristensen et al, 2011). Thus, measuring the
electrophysiological signature of transporter ligands can give direct information about the molecular mechanism of action for these substances. We found that 4-MEC, but not 4-MePPP, induces
inward current analogous to prototypical SERT substrates like fenfluramine and _p-_chloroamphetamine (Baumann et al, 2014; Gobbi et al, 2008). Moreover, the current dose–response
relationship with 4-MEC appears bell shaped, similar to the effects of other transporter substrates. The decrease in current measured at the highest concentration of 4-MEC (ie, 100 μM) is
likely because of the intracellular accumulation of substrate that tends to inhibit SERT-mediated current (Adams and DeFelice, 2003). We have previously shown that the magnitude of inward
current produced by SERT substrates may be involved in the persistent 5-HT depletions caused by these drugs in rats (Baumann et al, 2014; Gobbi et al, 2008). Our electrophysiological
findings with 4-MEC suggest that future studies should examine the potential for this drug to produce long-term serotonergic deficits in rodent models. Based on the present
structure–activity data, a crucial question arises: how does extending the _N_-alkyl chain of mephedrone produce major changes in pharmacology? We carried out molecular modeling studies to
address this question, with specific reference to the structural differences between 4-MEC (_N_-ethyl) and 4-MePPP (_N_-containing pyrrolidine ring) that lead to marked loss of activity at
SERT for 4-MePPP. Using a computational docking approach based on dDATcryst (Penmatsa et al, 2013), we show that the binding subpocket B of SERT is smaller because of bulkier amino-acid side
chains when compared with the binding subpocket of DAT. Therefore, it is tempting to speculate that SERT is less able to accommodate the bulky pyrrolidine ring structure of 4-MePPP when
compared with the smaller _N_-ethyl chain of 4-MEC. The present modeling approach may have key predictive value when attempting to understand transporter selectivity of new cathinone analogs
as they appear in the recreational drug marketplace. To summarize, the structure–activity data reported here demonstrate that changing the _N_-alkyl substituent of cathinone drugs can
profoundly influence their pharmacology. 4-MEC is a SERT substrate/DAT blocker with predominant 5-HT-releasing effects _in vivo_. The serotonergic actions of 4-MEC may reduce its stimulant
properties but enhance its propensity for producing long-term 5-HT deficits. 4-MePPP is a selective DAT blocker with robust locomotor stimulant effects _in vivo_. Although our study focused
on the effects of drugs on DAT and SERT, it seems likely that 4-MEC and 4-MePPP interact with NET as well (eg, see Simmler et al, 2014). Future studies should examine the neurotoxic
potential, abuse liability, and noradrenergic actions of 4-MEC, 4-MePPP, and other newly emerging cathinone derivatives. FUNDING AND DISCLOSURE HHS has received honoraria for lectures and
consulting from Lundbeck, Ratiopharm, Roche, Sanofi-Aventis, and Serumwerk Bernburg. The other authors declare no conflict of interest. REFERENCES * Aarde SM, Angrish D, Barlow DJ, Wright MJ
Jr, Vandewater SA, Creehan KM _et al_ (2013a). Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. _Addict Biol_ 18: 786–799.
Article CAS Google Scholar * Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013b). The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor
stimulant: self-administration and locomotor activity in rats. _Neuropharmacology_ 71: 130–140. Article CAS Google Scholar * Adams SV, DeFelice LJ (2003). Ionic currents in the human
serotonin transporter reveal inconsistencies in the alternating access hypothesis. _Biophys J_ 85: 1548–1559. Article CAS Google Scholar * Andersen J, Olsen L, Hansen KB, Taboureau O,
Jorgensen FS, Jorgensen AM _et al_ (2010). Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. _J Biol Chem_ 285: 2051–2063. Article
CAS Google Scholar * Ayres TC, Bond JW (2012). A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public
(ill)health. Legal highs or illegal highs? _BMJ Open_ 2: e000977. Article Google Scholar * Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF _et al_ (2012). The
designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. _Neuropsychopharmacology_ 37: 1192–1203. Article CAS Google Scholar *
Baumann MH, Bulling S, Benaderet TS, Saha K, Ayestas MA, Partilla JS _et al_ (2014). Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by
serotonin transporter substrates. _Neuropsychopharmacology_ 39: 1355–1365. Article CAS Google Scholar * Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (2011). _In vivo_
effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. _J Pharmacol Exp Ther_ 337: 218–225. Article CAS Google Scholar
* Baumann MH, Partilla JS, Lehner KR (2013a). Psychoactive “bath salts”: not so soothing. _Eur J Pharmacol_ 698: 1–5. Article CAS Google Scholar * Baumann MH, Partilla JS, Lehner KR,
Thorndike EB, Hoffman AF, Holy M _et al_ (2013b). Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products.
_Neuropsychopharmacology_ 38: 552–562. Article CAS Google Scholar * Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM _et al_ (2014). Hybrid dopamine uptake
blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. _ACS Med Chem Lett_ 5: 623–627. Article CAS Google Scholar * Bonano JS, Glennon RA, De Felice LJ,
Banks ML, Negus SS (2014). Abuse-related and abuse-limiting effects of methcathinone and the synthetic “bath salts” cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and
mephedrone on intracranial self-stimulation in rats. _Psychopharmacology_ 231: 199–207. Article CAS Google Scholar * Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (2011). Analysis
of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. _Drug Test Anal_ 3: 569–575. Article CAS Google Scholar * Cameron KN, Kolanos R, Solis E Jr, Glennon RA,
De Felice LJ (2013). Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. _Br J Pharmacol_ 168: 1750–1757. Article
CAS Google Scholar * Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). Bupropion and bupropion analogs as treatments for CNS disorders. _Adv Pharmacol_ 69:
177–216. Article CAS Google Scholar * Cercato C, Roizenblatt VA, Leanca CC, Segal A, Lopes Filho AP, Mancini MC _et al_ (2009). A randomized double-blind placebo-controlled study of the
long-term efficacy and safety of diethylpropion in the treatment of obese subjects. _Int J Obes_ 33: 857–865. Article CAS Google Scholar * Dargan PI, Sedefov R, Gallegos A, Wood DM
(2011). The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). _Drug Test Anal_ 3: 454–463. Article CAS Google Scholar * De Felice LJ, Glennon RA,
Negus SS (2014). Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. _Life Sci_ 97: 20–26. Article CAS Google Scholar * Drug Enforcement Administration (DEA),
Department of Justice (2013). Establishment of drug codes for 26 substances. Final rule. _Fed Regist_ 78: 664–666. Google Scholar * Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy
KV, Janowsky A (2013). Substituted methcathinones differ in transporter and receptor interactions. _Biochem Pharmacol_ 85: 1803–1815. Article CAS Google Scholar * Fantegrossi WE, Gannon
BM, Zimmerman SM, Rice KC (2013). _In vivo_ effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and
locomotor activity. _Neuropsychopharmacology_ 38: 563–573. Article CAS Google Scholar * Gatch MB, Taylor CM, Forster MJ (2013). Locomotor stimulant and discriminative stimulus effects of
‘bath salt' cathinones. _Behav Pharmacol_ 24: 437–447. Article CAS Google Scholar * Gil D, Adamowicz P, Skulska A, Tokarczyk B, Stanaszek R (2013). Analysis of 4-MEC in biological
and non-biological material—three case reports. _Forensic Sci Int_ 228: e11–e15. Article CAS Google Scholar * Gobbi M, Funicello M, Gerstbrein K, Holy M, Moya PR, Sotomayor R _et al_
(2008). N,N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant _in vitro_ efficacy for the induction of transporter-mediated
5-HT release and currents. _J Neurochem_ 105: 1770–1780. Article CAS Google Scholar * Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC _et al_ (2011). 4-Methylmethcathinone
(mephedrone): neuropharmacological effects of a designer stimulant of abuse. _J Pharmacol Exp Ther_ 339: 530–536. Article CAS Google Scholar * Hofmaier T, Luf A, Seddik A, Stockner T,
Holy M, Freissmuth M _et al_ (2014). Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. _Neurochem Int_ 73: 32–41.
Article CAS Google Scholar * Hou T, Wang J, Li Y, Wang W (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on
molecular dynamics simulations. _J Chem Inf Model_ 51: 69–82. Article CAS Google Scholar * Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997). Development and validation of a genetic
algorithm for flexible docking. _J Mol Biol_ 267: 727–748. Article CAS Google Scholar * Jorgensen WL, Maxwell DS, Tirado Rives J (1996). Development and testing of the OPLS all-atom
force field on conformational energetics and properties of organic liquids. _J Am Chem Soc_ 118: 11225–11236. Article CAS Google Scholar * Kehr J, Ichinose F, Yoshitake S, Goiny M,
Sievertsson T, Nyberg F _et al_ (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. _Br J
Pharmacol_ 164: 1949–1958. Article CAS Google Scholar * Kolanos R, Solis E Jr, Sakloth F, De Felice LJ, Glennon RA (2013). “Deconstruction” of the abused synthetic cathinone
methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. _ACS Chem Neurosci_ 4: 1524–1529. Article CAS Google Scholar * Kristensen AS, Andersen
J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ _et al_ (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. _Pharmacol Rev_ 63: 585–640. Article CAS Google
Scholar * Leffler AM, Smith PB, de Armas A, Dorman FL (2014). The analytical investigation of synthetic street drugs containing cathinone analogs. _Forensic Sci Int_ 234: 50–56. Article
CAS Google Scholar * Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA (2014). Emergence and properties of spice and bath salts: a medicinal chemistry perspective. _Life Sci_ 97:
9–19. Article CAS Google Scholar * Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012). Comparative neuropharmacology of three psychostimulant cathinone
derivatives: butylone, mephedrone and methylone. _Br J Pharmacol_ 167: 407–420. Article CAS Google Scholar * Marinetti LJ, Antonides HM (2013). Analysis of synthetic cathinones commonly
found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. _J Anal Toxicol_ 37: 135–146. Article CAS Google
Scholar * Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014). Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent
3,4-methylenedioxypyrovalerone (MDPV). _Neuropharmacology_ 87: 206–213. Article CAS Google Scholar * Marusich JA, Grant KR, Blough BE, Wiley JL (2012). Effects of synthetic cathinones
contained in “bath salts” on motor behavior and a functional observational battery in mice. _Neurotoxicology_ 33: 1305–1313. Article CAS Google Scholar * Meltzer PC, Butler D, Deschamps
JR, Madras BK (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. _J Med Chem_ 49: 1420–1432. Article CAS
Google Scholar * Penmatsa A, Wang KH, Gouaux E (2013). X-ray structure of dopamine transporter elucidates antidepressant mechanism. _Nature_ 503: 85–90. Article CAS Google Scholar *
Rojek S, Klys M, Maciow-Glab M, Kula K, Strona M (2014). Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and
4-methylethcathinone. _Drug Test Anal_ 6: 770–777. Article CAS Google Scholar * Rosenbaum CD, Carreiro SP, Babu KM (2012). Here today, gone tomorrow...and back again? A review of herbal
marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. _J Med Toxicol_ 8: 15–32. Article CAS Google Scholar *
Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. _Eur J Pharmacol_ 479: 23–40. Article CAS Google Scholar * Sali A, Potterton L, Yuan F, van Vlijmen H,
Karplus M (1995). Evaluation of comparative protein modeling by MODELLER. _Proteins_ 23: 318–326. Article CAS Google Scholar * Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH
(2000). Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. _J Pharmacol Exp Ther_ 293: 870–878. CAS Google
Scholar * Seddik A, Holy M, Weissensteiner R, Zdrazil B, Sitte HH, Ecker GF (2013). Probing the selectivity of monoamine transporter substrates by means of molecular modeling. _Mol Inform_
32: 409–413. Article CAS Google Scholar * Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J _et al_ (2013). Pharmacological characterization of designer cathinones _in
vitro_. _Br J Pharmacol_ 168: 458–470. Article CAS Google Scholar * Simmler LD, Rickli A, Hoener MC, Liechti ME (2014). Monoamine transporter and receptor interaction profiles of a new
series of designer cathinones. _Neuropharmacology_ 79: 152–160. Article CAS Google Scholar * Sitte HH, Freissmuth M (2010). The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter
transporters—why amphetamines take two to tango. _J Neurochem_ 112: 340–355. Article CAS Google Scholar * Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C (1998). Carrier-mediated
release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. _J Neurochem_ 71: 1289–1297.
Article CAS Google Scholar * Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG (1997). Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and
psychostimulants. _J Neurosci_ 17: 960–974. Article CAS Google Scholar * Spiller HA, Ryan ML, Weston RG, Jansen J (2011). Clinical experience with and analytical confirmation of “bath
salts” and “legal highs” (synthetic cathinones) in the United States. _Clin Toxicol_ 49: 499–505. Article CAS Google Scholar * Springer D, Fritschi G, Maurer HH (2003). Metabolism of the
new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas
chromatography-mass spectrometry. _J Chromatogr B Analyt Technol Biomed Life Sci_ 796: 253–266. Article CAS Google Scholar * Springer D, Peters FT, Fritschi G, Maurer HH (2002). Studies
on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. _J Chromatogr B Analyt
Technol Biomed Life Sci_ 773: 25–33. Article CAS Google Scholar * Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (2011). The ugly side of amphetamines: short- and long-term toxicity
of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy'), methamphetamine and D-amphetamine. _Biol Chem_ 392: 103–115. Article CAS Google Scholar * Tatsumi M, Groshan K, Blakely RD,
Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. _Eur J Pharmacol_ 340: 249–258. Article CAS Google Scholar * Thompson
JD, Gibson TJ, Higgins DG (2002). Multiple sequence alignment using ClustalW and ClustalX. _Curr Protoc Bioinformatics_ CHAPTER 2: Unit 2.3. PubMed Google Scholar * Wang H, Goehring A,
Wang KH, Penmatsa A, Ressler R, Gouaux E (2013). Structural basis for action by diverse antidepressants on biogenic amine transporters. _Nature_ 503: 141–145. Article CAS Google Scholar *
Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF _et al_ (2014). Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone
(MDPV). _Addict Biol_ 19: 165–174. Article CAS Google Scholar * Wilhelm BG, Mandad S, Truckenbrodt S, Krohnert K, Schafer C, Rammner B _et al_ (2014). Composition of isolated synaptic
boutons reveals the amounts of vesicle trafficking proteins. _Science_ 344: 1023–1028. Article CAS Google Scholar * Wright MJ Jr, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM
_et al_ (2012). Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. _PLoS One_ 7: e44652.
Article CAS Google Scholar * Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC (2000). Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters.
_Bioorg Med Chem_ 8: 2689–2692. Article CAS Google Scholar * Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V _et al_ (2009). Evidence for the involvement of dopamine
transporters in behavioral stimulant effects of modafinil. _J Pharmacol Exp Ther_ 329: 738–746. Article CAS Google Scholar Download references ACKNOWLEDGEMENTS This research was supported
by the Austrian Research Fund/FWF grants F3506 and W1232 to HHS and the Intramural Research Program of the NIDA, NIH, grant DA000523-07 to MHB. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *
Medical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Vienna, Austria Kusumika Saha, Thomas Stockner, Marion Holy, Walter Sandtner & Harald H
Sitte * Designer Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, Baltimore, MD, USA John S Partilla, Kurt R Lehner & Michael H Baumann * Department of
Pharmaceutical Sciences, University of Vienna, Vienna, Austria Amir Seddik & Gerhard F Ecker * Medical University of Vienna, Center for Addiction Research and Science, Vienna, Austria
Harald H Sitte Authors * Kusumika Saha View author publications You can also search for this author inPubMed Google Scholar * John S Partilla View author publications You can also search for
this author inPubMed Google Scholar * Kurt R Lehner View author publications You can also search for this author inPubMed Google Scholar * Amir Seddik View author publications You can also
search for this author inPubMed Google Scholar * Thomas Stockner View author publications You can also search for this author inPubMed Google Scholar * Marion Holy View author publications
You can also search for this author inPubMed Google Scholar * Walter Sandtner View author publications You can also search for this author inPubMed Google Scholar * Gerhard F Ecker View
author publications You can also search for this author inPubMed Google Scholar * Harald H Sitte View author publications You can also search for this author inPubMed Google Scholar *
Michael H Baumann View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Michael H Baumann. POWERPOINT SLIDES POWERPOINT
SLIDE FOR FIG. 1 POWERPOINT SLIDE FOR FIG. 2 POWERPOINT SLIDE FOR FIG. 3 POWERPOINT SLIDE FOR FIG. 4 POWERPOINT SLIDE FOR FIG. 5 POWERPOINT SLIDE FOR FIG. 6 RIGHTS AND PERMISSIONS Reprints
and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Saha, K., Partilla, J., Lehner, K. _et al._ ‘Second-Generation’ Mephedrone Analogs, 4-MEC and 4-MePPP, Differentially Affect Monoamine
Transporter Function. _Neuropsychopharmacol_ 40, 1321–1331 (2015). https://doi.org/10.1038/npp.2014.325 Download citation * Received: 05 September 2014 * Revised: 07 November 2014 *
Accepted: 09 November 2014 * Published: 15 December 2014 * Issue Date: May 2015 * DOI: https://doi.org/10.1038/npp.2014.325 SHARE THIS ARTICLE Anyone you share the following link with will
be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt
content-sharing initiative